Intelligence Unit
Special Reports
Special Events
Subscribe
Sponsored
Departments
- Leadership
- Finance
- Technology
- Physicians
- Community Hospitals
- Health Plans
- Marketing
- Quality
- Nursing
- HR
Follow Us
Imaging Rates Scrutinized; Conclusions Mixed
Older Medicare beneficiaries with a diagnosis of stage IV cancer receive expensive advanced imaging tests at steadily increasing rates, despite limited proof of benefit.
That's according to a study in the Journal of the American Cancer Society July 30 by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the University of Wisconsin Surgical Outcomes Research Program.
During the study, these tests, which included CT, MRI, PET (positron emission tomography), and nuclear medicine scans, continued to increase even after the patients were scanned to determine that they had reached stage IV.
"Although many of these procedures occurred during the diagnostic phase...the majority did not," wrote lead author Caprice C. Greenberg, MD, director of the Wisconsin program, and colleagues. "Three-quarters of patients were scanned during the continuing care phase; on average, including patients who had no tests, patients were scanned every 6 weeks."
- Patient Harm Data to Remain on Medicare's Hospital Compare Site
- Quiet ORs Better for Patient Safety
- Tavenner Confirmed as CMS Administrator
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Leapfrog Hospital Safety Scores 'Depressing'
- Building a Better Healthcare Board
- Hard-Nosed About Physician Teamwork
- Case Study: Advance Care Conversations
- Healthcare Leaders Sound Off on Organized Labor
- CMS Releases Hospital Pricing Data
Comments are moderated. Please be patient.
Ryan Grote (8/6/2012 at 11:00 PM)
These findings are congruent with work that Memorial Hermann has been developing in Houston to standardize order sets to help support the clinical team focus on what they do best- develop a plan of care for patients- while using the guidelines of limited resources, in this instance, money. I am hopeful to see more evidence that drives to stronger clinical paths and better outcomes for patients, and the rest of us